Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine

Lipids in Health and Disease

Luis A Touceda²  Nelva T de Gómez Dumm¹ 

[1] Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP-CONICET-UNLP);Cátedra de Medicina Interna, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, 60 y 120, 1900, La Plata, Argentina. Fax: 54:221 4258988

关键词: triglyceride;    pyridoxine;    polyunsaturated fatty acids;    homocysteine;    chronic renal failure;    cholesterol;   

Others  :  1213320
DOI  :  10.1186/1476-511X-2-7

 received in 2003-08-28, accepted in 2003-09-18,  发布年份 2003

【 摘 要 】

Background

Hyperhomocysteinemia and lipid abnormalities are commonly found in patients with chronic renal failure; both are recognized as risk factors for atherosclerosis. The homocysteine-lowering effect of pyridoxine is controversial. This study was performed to determine the effect of a high dose of pyridoxine (300 mg i.v. three times a week) on plasma and red blood cell lipid profile and plasma homocysteine concentration in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (basal 1), after 30 and 60 days of treatment and 4 months after withdrawal (basal 2).

Results

Pyridoxine supplementation induced a significant decrease in total plasma homocysteine level and also a lowering effect in plasma total cholesterol and triglycerides. These biochemical data increased when the samples were taken at basal 2, reaching the levels obtained at the beginning of the experiment. LDL cholesterol increased whereas HDL cholesterol was reduced during the treatment. In erythrocyte membranes vitamin B6 therapy enhanced the cholesterol/phospholipid ratio as well as the fluorescence anisotropy of diphenyl-hexatriene.

Conclusions

We conclude that high doses of pyridoxine represent an effective strategy to ameliorate both plasma homocysteine levels and lipid profiles in chronic renal failure patients, protecting them from atherosclerosis. Further research using a long-term treatment would be necessary in an attempt to restore the fatty acid pattern and the fluidity of red cell membranes.

【 授权许可】

   
2003 de Gómez Dumm et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Zoccali C: Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant 2000, 15:454-457.
• [2]Green D, Stone NJ, Krumlowsky A: Putative atherogenic factors in patients with chronic renal failure. Prog Cardiovascular Dis 1983, 26:133-144.
• [3]Jeppesen J, Hein JO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen male study. Circulation 1998, 97:1029-1036.
• [4]Assman G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol 1992, 70:733-737.
• [5]Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovascular Risk 1996, 3:213-219.
• [6]Gómez Dumm INT de, Giammona AM, Touceda LA, Raimondi C: Lipid abnormalities in chronic renal failure patients undergoing hemodialysis. Medicina 2001, 61:142-146.
• [7]Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioescler Throm Vasc Biol 1997, 11:2554-2558.
• [8]Hankey GJ, Eikelboom JW: Homocysteine and vascular disease. Lancet 1999, 354:407-413.
• [9]Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer E, El Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentration. Circulation 1996, 94:2742-2748.
• [10]Dennis VW, Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996, 57 Suppl:S11-S17.
• [11]Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G, et al.: Plasma homocysteine as a risk factor for vascular disease. JAMA 1997, 277:1775-1781.
• [12]Mallamaci I, Zoccali C, Tripeti G, Fermo I., Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney International 2002, 61:609-614.
• [13]Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willett WC: Homocysteine metabolism and risk of myocardial infarction – relation with vitamin B-6, vitamin B-12, and folate. Am J Epidemiol 1996, 143:845-859.
• [14]Henning BF, Riezler R, Tepel M, Langer K, Raidt H, Graefe U, Zidek W: Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 1999, 83:314-322.
• [15]Tremblay R, Bonnardeaux A, Geadah D, Busque L, Lebrun M, Ouimet D, Leblanc M: Hyperhomocysteinemia in hemodialysis patients: effects of 12 month supplementation with hydrosoluble vitamins. Kidney Int 2000, 58:851-858.
• [16]Bostom AG, Shemin D, Lapane KL: Hyperhomocysteinemia and traditional cardiovasculardisease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995, 114:93-103.
• [17]Gómez Dumm NTde, Giammona AM, Touceda L: Variations in the lipid profile of patients with chronic renal failure, treated with folic acid. Int J Vitam Nutr Res 2003, 73:215-220.
• [18]Touceda LA, Arroyo D, Giammona AM, Onofri MF, Iglesias O, Bruseghini S, Bruzzo L, Ruiz de la Fuente ME: Efecto de megadosis intravenosas de ácido fólico sobre la homocisteína en pacientes en hemodiálisis. Rev Nefrol Dial y Traspl 2001, 55:21-28.
• [19]Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Shelhub J, Rosenberg I: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996, 49:147-152.
• [20]Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentration in dialysis patients. Clin Nephrol 1993, 40:236-240.
• [21]Chaveau P, Chadefaux B, Coude M, Aupetit J, Kamoun P, Jungers P: Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996, 22:106-109.
• [22]Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drüeke T, Massy ZA: Effective correction of hyperhomocyst(e)inemia in hemodialysis patients by i.v. folinic acid and piridoxine therapy. Kidney Int 1999, 56:2292-2296.
• [23]McKinley MC, McNulty H, McPartlin J, Strain JJ, Pentieva K, Ward M, Weir DG, Scott JM: Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr 2001, 73:759-764.
• [24]Frantzen F, Faaren AL, Alfheim I, Nordhei AK: Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998, 44:311-316.
• [25]Kaysen GA: Hyperlipidemia of chronic renal failure. Blood Purif 1994, 12:60-67.
• [26]Peck LW, Monsen ER, Ahmad S: Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am J Clin Nut 1996, 64:210-214.
• [27]Dasgupta A, Kenny MA, Ahmad S: Abnormal fatty acid profile in chronic hemodialysis patients: possibly deficiency of essential fatty acids. Clin Physiol Biochem 1990, 8:238-243.
• [28]Koorts AM, Viljoen M, Kruger MC: Red blood cell fatty acid profile in chronic renal failure patients receiving maintenance haemodialysis treatment. Prostaglandins Leukot Essent Fatty Acids 2002, 67:13-18.
• [29]Siguel E: A new relationship between total/high density lipoprotein cholesterol and polyunsaturated fatty acids. Lipids 1996, 31:S51-S56.
• [30]Siguel EN, Lerman RH: Fatty acid patterns in patients with angiographically documented coronary artery disease. Metabolism 1994, 43:982-993.
• [31]Sinclair H: Dietary fats and coronary heart disease. Controversy. Lancet 1980, i:414-415.
• [32]Kingsbury KJ, Brett C, Stovold R, Chapman A, Anderson J, Morgan DM: Abnormal fatty acid composition and human atherosclerosis. Postgrad Med J 1974, 285:425-440.
• [33]Kingsbury KJ: Polyunsaturated fatty acids and myocardial infraction. Lancet 1970, i:648-676.
• [34]Berlin E, Bathena SJ, Judd JHT, Nair PP, Jones DY, Taylor PR: Dietary fat and hormone effects on erythrocyte membrane fluidity and lipid composition in adult women. Metabolism 1989, 38:790-796.
• [35]Stubbs CD, Smith AS: The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 1984, 779:89-137.
• [36]Garda HA, Brenner RR: Short-chain aliphatic alcohols increase rat liver microsomal membrane fluidity and affect the activities of some microsomal membrane-bound enzymes. Biochim Biophys Acta 1984, 769:160-170.